|
|
 Previous Article | Table of Contents | Next Article 
'Role of bone marrow stromal cells in the growth of human multiple myeloma
F Caligaris-Cappio, L Bergui, MG Gregoretti, G Gaidano, M Gaboli, M Schena, AZ Zallone and PC Marchisio
Departimento di Scienze Biomediche e Oncologia Umana,Sezione Clinica and
Sezione di Istologia, Universita di Torino, Italy.
We have verified the hypothesis that multiple myeloma (MM) may be
disseminated by circulating clonogenic cells that selectively home to the
bone marrow (BM) to receive the signal(s) leading to proliferation,
terminal differentiation, and production of the osteoclast activating
factors. Long-term cultures of stromal cells have been developed from the
BM of nine patients with MM. These cells were mostly fibroblast- like
elements, interspersed with a proportion of scattered macrophages and rare
osteoclasts. BM stromal cells were CD54+, produced high levels of
interleukin-6 (IL-6) and measurable amounts of IL-1 beta, and were used as
feeder layers for autologous peripheral blood mononuclear cells (PBMC).
After 3 weeks of cocultures, monoclonal B lymphocytes and plasma cells,
derived from PBMC, developed and the number of osteoclasts significantly
increased. Both populations grew tightly adherent to the stromal cell layer
and their expansion was matched by a sharp increase of IL-6 and by the
appearance of IL-3 in the culture supernatant. These data attribute to BM
stromal cells a critical role in supporting the growth of B lymphocytes,
plasma cells, and osteoclasts and the in vivo dissemination of MM.
Volume 77,
Issue 12,
pp. 2688-2693,
06/15/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Kirshner, K. J. Thulien, L. D. Martin, C. Debes Marun, T. Reiman, A. R. Belch, and L. M. Pilarski
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma
Blood,
October 1, 2008;
112(7):
2935 - 2945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Huff and W. Matsui
Multiple Myeloma Cancer Stem Cells
J. Clin. Oncol.,
June 10, 2008;
26(17):
2895 - 2900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kukreja, A. Hutchinson, K. Dhodapkar, A. Mazumder, D. Vesole, R. Angitapalli, S. Jagannath, and M. V. Dhodapkar
Enhancement of clonogenicity of human multiple myeloma by dendritic cells
J. Exp. Med.,
August 7, 2006;
203(8):
1859 - 1865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Menu, H. Jernberg-Wiklund, T. Stromberg, H. De Raeve, L. Girnita, O. Larsson, M. Axelson, K. Asosingh, K. Nilsson, B. Van Camp, et al.
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
Blood,
January 15, 2006;
107(2):
655 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby
The Phenotypic Plasticity of Myeloma Plasma Cells as Expressed by Dedifferentiation into an Immature, Resilient, and Apoptosis-Resistant Phenotype
Clin. Cancer Res.,
November 1, 2005;
11(21):
7599 - 7606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tassone, P. Neri, R. Burger, R. Savino, M. Shammas, L. Catley, K. Podar, D. Chauhan, S. Masciari, A. Gozzini, et al.
Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma
Clin. Cancer Res.,
June 1, 2005;
11(11):
4251 - 4258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Mori, N. Shimizu, M. Dallas, M. Niewolna, B. Story, P. J. Williams, G. R. Mundy, and T. Yoneda
Anti-{alpha}4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis
Blood,
October 1, 2004;
104(7):
2149 - 2154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, M. J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, and J. Epstein
Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model
Cancer Res.,
March 15, 2004;
64(6):
2016 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bisping, R. Leo, D. Wenning, B. Dankbar, T. Padro, M. Kropff, C. Scheffold, M. Kroger, R. M. Mesters, W. E. Berdel, et al.
Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma
Blood,
April 1, 2003;
101(7):
2775 - 2783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Calabro, M. M. Oken, V. C. Hascall, and A. M. Masellis
Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients
Blood,
September 18, 2002;
100(7):
2578 - 2585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. S. Shapiro, M. N. Mollenauer, and A. Weiss
Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression
Blood,
July 1, 2001;
98(1):
187 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chesi, L. A. Brents, S. A. Ely, C. Bais, D. F. Robbiani, E. A. Mesri, W. M. Kuehl, and P. L. Bergsagel
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
Blood,
February 1, 2001;
97(3):
729 - 736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Frassanito, A. Cusmai, G. Iodice, and F. Dammacco
Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis
Blood,
January 15, 2001;
97(2):
483 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Michigami, N. Shimizu, P. J. Williams, M. Niewolna, S. L. Dallas, G. R. Mundy, and T. Yoneda
Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha 4beta 1-integrin enhances production of osteoclast-stimulating activity
Blood,
September 1, 2000;
96(5):
1953 - 1960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asosingh, U. Gunthert, M. H. C. Bakkus, H. De Raeve, E. Goes, I. Van Riet, B. Van Camp, and K. Vanderkerken
In Vivo Induction of Insulin-like Growth Factor-I Receptor and CD44v6 Confers Homing and Adhesion to Murine Multiple Myeloma Cells
Cancer Res.,
June 1, 2000;
60(11):
3096 - 3104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Dankbar, T. Padro, R. Leo, B. Feldmann, M. Kropff, R. M. Mesters, H. Serve, W. E. Berdel, and J. Kienast
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
Blood,
April 15, 2000;
95(8):
2630 - 2636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Vanderkerken, K. Asosingh, F. Braet, I. Van Riet, and B. Van Camp
Insulin-Like Growth Factor-1 Acts as a Chemoattractant Factor for 5T2 Multiple Myeloma Cells
Blood,
January 1, 1999;
93(1):
235 - 241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Tisdale, A. K. Stewart, B. Dickstein, R. F. Little, I. Dube, D. Cappe, C. E. Dunbar, and K. E. Brown
Molecular and Serological Examination of the Relationship of Human Herpesvirus 8 to Multiple Myeloma: orf 26 Sequences in Bone Marrow Stroma Are Not Restricted to Myeloma Patients and Other Regions of the Genome Are Not Detected
Blood,
October 15, 1998;
92(8):
2681 - 2687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Szczepek, K. Seeberger, J. Wizniak, M. J. Mant, A. R. Belch, and L. M. Pilarski
A High Frequency of Circulating B Cells Share Clonotypic Ig Heavy-Chain VDJ Rearrangements With Autologous Bone Marrow Plasma Cells in Multiple Myeloma, as Measured by Single-Cell and In Situ Reverse Transcriptase-Polymerase Chain Reaction
Blood,
October 15, 1998;
92(8):
2844 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Fracchiolla, S. Luminari, L. Baldini, L. Lombardi, A. T. Maiolo, and A. Neri
FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple Myeloma
Blood,
October 15, 1998;
92(8):
2987 - 2989.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Hauser, M. C. Allewelt, and D. A. Lipschitz
Effects of Myelotoxic Agents on Cytokine Production in Murine Long-Term Bone Marrow Cultures
Stem Cells,
July 1, 1998;
16(4):
261 - 270.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. V. Dhodapkar, E. Abe, A. Theus, M. Lacy, J. K. Langford, B. Barlogie, and R. D. Sanderson
Syndecan-1 Is a Multifunctional Regulator of Myeloma Pathobiology: Control of Tumor Cell Survival, Growth, and Bone Cell Differentiation
Blood,
April 15, 1998;
91(8):
2679 - 2688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood,
January 1, 1998;
91(1):
3 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, G. Teoh, D. Chauhan, Y. Hoshi, A. Ogata, S. P. Treon, R. L. Schlossman, and K. C. Anderson
Interleukin-6 Overcomes p21WAF1 Upregulation and G1 Growth Arrest Induced by Dexamethasone and Interferon-gamma in Multiple Myeloma Cells
Blood,
July 1, 1997;
90(1):
279 - 289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.V.B. Emmons, S. Doren, J. Zujewski, M. Cottler-Fox, C.S. Carter, K. Hines, J.A. O'Shaughnessy, S.F. Leitman, J.J. Greenblatt, K. Cowan, et al.
Retroviral Gene Transduction of Adult Peripheral Blood or Marrow-Derived CD34+ Cells for Six Hours Without Growth Factors or on Autologous Stroma Does Not Improve Marking Efficiency Assessed In Vivo
Blood,
June 1, 1997;
89(11):
4040 - 4046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Hauser, O. Kajkenova, and D. A. Lipschitz
The Pivotal Role of Interleukin 6 in Formation and Function of Hematopoietically Active Murine Long-Term Bone Marrow Cultures
Stem Cells,
March 1, 1997;
15(2):
125 - 132.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Chauhan, S. Kharbanda, A. Ogata, M. Urashima, G. Teoh, M. Robertson, D. W. Kufe, and K. C. Anderson
Interleukin-6 Inhibits Fas-Induced Apoptosis and Stress-Activated Protein Kinase Activation in Multiple Myeloma Cells
Blood,
January 1, 1997;
89(1):
227 - 234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
